Innehållet nedan modereras inte i förväg och omfattas därmed inte av webbplatsens utgivningsbevis.

Collaboration between Zerion (DK) and Insud Pharma (ES)

| Medlemsnyhet | Företag Zerion Pharma A/S

Zerion Pharma and Insud Pharma announce collaboration to develop Dispersome® formulations of marketed drug products.

The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop and commercialize drug products applying ZERION’s solubility enhancing Dispersome® technology. ZERION will develop Dispersome® formulations of marketed drug products while INSUD PHARMA will be responsible for the finished product dosage form, the clinical development as well as global marketing and sales of the final products.

INSUD PHARMA and ZERION started working together in 2021 and the partnership has now resulted in the first Dispersome® drug product being ready for upscaling, GMP manufacture, and human clinical trials. ZERION has granted INSUD PHARMA a worldwide exclusive license to this first Dispersome® drug formulation. Under the terms of the license agreement, INSUD PHARMA will pay ZERION license fees, as well as milestone fees and royalties on product sales. INSUD will cover all clinical and other development costs.

Read the full press release here.


Zerion Pharma A/S

Fruebjergvej 3
2100 Copenhagen
Zerion Pharma A/S

Sänd till en kollega